Candidiasis News and Research

RSS

Candiadiasis, or Thrush, is a fungal infection caused by a group of yeast. There is a score of Candida species, the commonest of which is Candida albicans. They normally inhabit the surfaces and mucus linings of the human body. This includes mouth, vaginal cavity gastrointestinal tract etc.

BioAlliance Pharma, Vestiq enter license agreement for Oravig to treat oropharyngeal candidiasis

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces it has signed a binding term sheet with Vestiq for the commercialization rights in the United States of Oravig (known as Loramyc in Europe) for the treatment of oropharyngeal candidiasis in adults.

20 Jul 2012

Sosei completes SO-1105 Phase I trial for oropharyngeal candidiasis in Japan

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has successfully completed a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

2 Jul 2012

NovaDigm reports positive data from Phase 1 NDV-3 vaccine program

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study.

7 May 2012

Sosei initiates SO-1105 Phase I trial in oropharyngeal candidiasis

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

8 Mar 2012

Candida albicans can sense immune status of host cells and evade them

Glen Palmer, PhD, Assistant Professor of Microbiology, Immunology & Parasitology at LSU Health Sciences Center New Orleans, was part of an international research team led by Luigina Romani, MD, at the University of Perugia, that discovered opportunistic fungi like Candida albicans can sense the immune status of host cells and adapt, evading immune system defenses.

23 Feb 2012

Affinium initiates AFN-1252 Phase 2 trial in acute bacterial skin & skin structure infections

Affinium Pharmaceuticals announced today dosing of the first patient in a multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections.

1 Feb 2012

Woman's ovarian cycle plays an important role in her susceptibility to infection

A new research report in the Journal of Leukocyte Biology suggests that a woman's ovarian cycle plays an important role in her susceptibility to infection.

4 Jan 2012

Effective ways to reduce risk of vaginal yeast infection

Vaginal thrush is one of the most popular topics on NHS Choices website. This common yeast infection affects around 75% (three-quarters) of women at some point. Up to half of these will have thrush more than once.

21 Oct 2011

Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data from a preclinical study evaluating the efficacy its NDV-3 vaccine in a model of vulvovaginal candidiasis (VVC), which is primarily caused by Candida albicans.

20 Sep 2011

Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.

14 Sep 2011

Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that the Company will present positive data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 17-20, 2011 in Chicago, IL.

13 Sep 2011

Researchers discover how yeast cells identify, attach to human tissue and cause infection

Researchers are a step closer towards creating a new class of medicines and vaccines to combat drug-resistant and deadly strains of fungal infections, following a new study published today in Proceedings of the National Academy of Sciences.

6 Sep 2011

PolyMedix presents new pre-clinical data on antimicrobial compounds at two scientific meetings

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced today that new pre-clinical data for its novel, defensin-mimetic antimicrobial compounds was recently presented at two prestigious scientific meetings, including the American Society of Microbiology.

25 May 2011

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

11 May 2011

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Sosei Group Corporation, the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc (miconazole Lauriad) in Japan from BioAlliance Pharma.

11 May 2011

Hi-Tech Pharmacal acquires rights to Nystatin Oral suspension ANDA from Bausch + Lomb

Hi-Tech Pharmacal Co., Inc. announced that it has acquired the rights to the Abbreviated New Drug Application (ANDA) for Nystatin Oral suspension from Bausch + Lomb, the global eye health company for an undisclosed upfront payment and a future royalty.

21 Mar 2011

Spine surgeon successfully treated with RNL Bio's stem cell therapy for Autoimmune Arthritis

RNL BIO CO., LTD, a leading biopharmaceutical company specialized in adult stem cell therapeutics, announced on January 21, 2011 another successful patient report utilizing stem cell therapy on a leading US orthopedic spine surgeon who suffered from Autoimmune Arthritis.

26 Jan 2011

Pevion announces positive results of PEV7 Phase I study for recurrent vulvovaginal candidiasis

Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC).

11 Nov 2010

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced that data from two separate pre-clinical research studies were published in the December issue of Molecular Oral Microbiology.

10 Nov 2010

NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.

30 Sep 2010